Browsing Clinical Studies by author "Minchom, Anna"
Now showing items 21-25 of 25
-
Statistical methods and data visualisation of patient-reported outcomes in early phase dose-finding oncology trials: a methodological review.
Alger, E; Minchom, A; Lee Aiyegbusi, O; Schipper, M; Yap, C (ELSEVIER, 2023-10-01)BACKGROUND: Traditionally, within dose-finding clinical trials, treatment toxicity and tolerability are assessed by clinicians. Research has shown that clinician reporting may have inadequate inter-rater reliability, poor ... -
Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT).
Pal, A; Stapleton, S; Yap, C; Lai-Kwon, J; Daly, R; et al. (BMJ PUBLISHING GROUP, 2021-09-06)INTRODUCTION: Early phase cancer clinical trials have become increasingly complicated in terms of patient selection and trial procedures-this is reflected in the increasing length of participant information sheets (PIS). ... -
Trends in patient-reported outcome use in early phase dose-finding oncology trials - an analysis of ClinicalTrials.gov.
Lai-Kwon, J; Yin, Z; Minchom, A; Yap, C (WILEY, 2021-11-01)BACKGROUND: Patient-reported adverse events (AEs) may be a useful adjunct to clinician-assessed AEs for assessing tolerability in early phase, dose-finding oncology trials (DFOTs). We reviewed DFOTs on ClinicalTrials.gov ... -
Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
Cui, W; Milner-Watts, C; O'Sullivan, H; Lyons, H; Minchom, A; et al. (ELSEVIER SCI LTD, 2022-08-01)BACKGROUND: Genomic sequencing is necessary for first-line advanced non-small cell lung cancer (aNSCLC) treatment decision-making. Tissue next generation sequencing (NGS) is standard but tissue quantity, quality, and ... -
Using Patient-Reported Outcomes in Dose-Finding Oncology Trials: Surveys of Key Stakeholders and the National Cancer Research Institute Consumer Forum.
Lai-Kwon, J; Vanderbeek, AM; Minchom, A; Lee Aiyegbusi, O; Ogunleye, D; et al. (OXFORD UNIV PRESS, 2022-09-02)BACKGROUND: Patient-reported adverse events may be a useful adjunct for assessing a drug's tolerability in dose-finding oncology trials (DFOT). We conducted surveys of international stakeholders and the National Cancer ...